p-tau217 predicts absolute risk of cognitive decline in unimpaired adults

A JAMA 2026 study quantifies that cognitively unimpaired adults with elevated p-tau217 have a 24% (high) and 38% (very high) risk of cognitive decline over 5 years. While not yet for clinical use, these concrete numbers help families weigh risk and support the biomarker's prognostic value.